Onco-Innovations Limited (CBOE CA: ONCO; Frankfurt: W1H, WKN: A3EKSZ) is proud to announce the appointment of Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. This key appointment underscores the Company’s dedication to advancing oncology innovation through expert-driven translational research and clinical excellence.
Dr. Mohamed is a seasoned Radiation Oncologist, clinical researcher, and biotechnology advisor with over 20 years of experience at the forefront of cancer care and innovation. He holds an Honours BSc in Genetics and completed his specialty training in Radiation Oncology in 2000. Currently practicing at BC Cancer, he has built a distinguished clinical career focusing on lung, breast, skin cancers, and sarcoma. He is widely recognized for his expertise in stereotactic radiation therapy and precision oncology.
Throughout his career, Dr. Mohamed has led numerous clinical trials at institutional and provincial levels, significantly contributing to the evolution of treatment strategies for breast, lung, and oligometastatic cancers. His work on national clinical trial committees and research ethics boards has helped shape Canadian standards for oncology care and clinical research governance.
In addition to his clinical and academic accomplishments, Dr. Mohamed is deeply engaged in Canada’s biotech innovation ecosystem. He serves as an advisor and investor in several early-stage biotech companies, including Linax Technologies, IllumiSonics, and Asep Medical. His focus is on transformative diagnostic tools, therapeutic platforms, and breakthrough technologies with strong translational potential. His unique blend of clinical, research, and entrepreneurial expertise makes him a strategic leader in evaluating innovation and guiding R&D strategy.
As Chair of the Scientific and Clinical Advisory Board, Dr. Mohamed will play a pivotal role in shaping Onco-Innovations’ R&D roadmap. The Board’s mandate includes providing strategic guidance on research priorities, enabling clinical and scientific partnerships, and ensuring the integration of independent scientific insights into the Company’s decision-making processes.
“We are delighted to welcome Dr. Mohamed to our leadership team,” said Thomas O’Shaughnessy, CEO of Onco-Innovations. “His extensive experience in oncology, clinical research, and biotech innovation will be invaluable as we accelerate the development of novel cancer solutions and expand our translational research programs.”
This appointment reflects Onco-Innovations’ strategic focus on bridging cutting-edge science with clinical impact to improve outcomes for cancer patients worldwide.